Xoma | XOMA - Operating Profit


Xoma reported $-15.64M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Agenus USD 14.4M 19.26M Dec/2025
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Ardelyx USD 5.1M 431K Dec/2025
aTyr Pharma USD 24.47M 51.21M Dec/2025
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Celldex Therapeutics USD -84.44M 2.72M Mar/2026
Curis USD -7.88M 4.63M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Emergent BioSolutions USD -218M 69.9M Jun/2023
Incyte USD 324.17M 59.7M Mar/2026
MacroGenics USD -12.1M 30.74M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Novartis USD 4.06B 521M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
Prothena USD -27.21M 12.55M Dec/2025
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Xoma USD -15.64M 5.56M Sep/2024